Pacific Biosciences is trading 5.37% down at $2.58 on October 7, 2026; no new company-specific catalyst was identified.
- October 6 TychoBio collaboration aims to generate RNA-sequencing data from more than 10,000 samples; coverage called the prior-session drop a breather after an eight-session rally that more than doubled shares, not a reaction to negative news.
- Rising Treasury yields and caution ahead of Fed minutes may add biotech pressure; XBI is down 2.50%, major U.S. indexes are lower, and the run-up may leave shares vulnerable to a pullback.